Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03574571 · ClinicalTrials.gov registry record · Phase 3
A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer
A Phase 3 study of Prostate Cancer, sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- Phase 3
- Development phase
- 732
- Enrollment target
- 20
- Study locations
NCT03574571: Active Phase 3 study of Prostate Cancer, sponsored by Memorial Sloan Kettering Cancer Center.
NCT03574571 is a Phase 3 study of Prostate Cancer that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 732 participants, above the 607-participant average among 735 other Prostate Cancer trials with a reported enrollment target (21% higher). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03574571, a Phase 3 study of Prostate Cancer, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 732 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to compare any good and bad effects of using radium-223 along with docetaxel chemotherapy treatment versus using docetaxel alone. Earlier studies helped show that the combination is safe, but the combination has not been proven to work better than either drug alone. The goal of this study is to find out if combining docetaxel and radium-223 is better than giving either drug by itself.
Primary Outcome
Overall survival is defined as the time from randomization to death from any cause.
Conditions Studied
Interventions
- DRUG Radium-223
- DRUG Docetaxel 75 mg/m2
- DRUG Docetaxel 60 mg/m2
Study Locations (20)
New Jersey
- Memorial Sloan Kettering Basking Ridge - Basking Ridge
- MD Anderson Cancer Center at Cooper - Camden
- Memorial Sloan Kettering Monmouth - Middletown
- Memorial Sloan Kettering Bergen - Montvale
- New Jersey Urology - Saddle Brook
Florida
- Boca Raton Regional Hospital - Boca Raton
- Mount Sinai Medical Center (Miami) - Miami
Nebraska
- Nebraska Cancer Specialists - Omaha
- XCancer Omaha / Urology Cancer Center - Omaha
Arizona
- Banner MD Anderson Cancer Center - Gilbert
Connecticut
- Yale University- Yale Cancer Center - New Haven
Delaware
- Helen Graham Cancer Center (Christiana Care) - Newark
Illinois
- Rush University Medical Center - Chicago
Indiana
- Indiana University - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 732 participants |
| Start Date | 2018-06-19 |
| Est. Completion | 2027-04-01 |
| Phase | Phase 3 |
What the registry record for NCT03574571 still lists
NCT03574571 is an interventional study that assigns participants to a tested intervention. The registered 732 participants enrollment target is mid-sized for trials with a published cap, above the 607-participant average among 735 other Prostate Cancer trials with a reported enrollment target (21% higher).
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 3 interventions - of which Radium-223 is the first listed.
NCT03574571 names 20 study sites across 14 states, led by New Jersey, Florida, Nebraska.
Frequently Asked Questions
What is clinical trial NCT03574571 about?
NCT03574571 is a clinical study titled "A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer". The purpose of this study is to compare any good and bad effects of using radium-223 along with docetaxel chemotherapy treatment versus using docetaxel alone. Earlier studies helped show that the combination is safe, but the combination has not been proven to work better than either drug alone. The ...
What is the current status of trial NCT03574571?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 732 participants. The study started on 2018-06-19. Estimated completion is 2027-04-01.
What conditions does trial NCT03574571 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT03574571?
The interventions under investigation include: Radium-223 (DRUG), Docetaxel 75 mg/m2 (DRUG), Docetaxel 60 mg/m2 (DRUG).
Who is sponsoring clinical trial NCT03574571?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03574571 being conducted?
This trial has 20 study locations across Arizona, Connecticut, Delaware, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03574571's enrollment target sits among peer trials
732 85th of 735 higher than 651 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer
RECRUITING · Phase 3
-
PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.
RECRUITING · Phase 3
-
Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment
RECRUITING · Phase 3
-
Robotic Opioid-free Prostatectomy Enhanced Strategy (ROPES)
RECRUITING · Phase 3
-
SAFE Nerve Sparing Guided by Micro-ultrasound (MUS)
RECRUITING · Phase 3
-
Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06216301 · 734 participants · Phase 3
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
- NCT07231419 · 734 participants · Phase 3
Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy
- NCT03232918 · 730 participants · Phase 4
Oxytocin and Fetal Heart Rate Changes
- NCT05548283 · 730 participants · Phase 4
Standardizing Treatments for Pulmonary Exacerbations - Aminoglycoside Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI